"10.1371_journal.pone.0083139","plos one","2013-12-23T00:00:00Z","Nahzli Dilek; Nicolas Poirier; Philippe Hulin; Flora Coulon; Caroline Mary; Simon Ville; Henri Vie; Béatrice Clémenceau; Gilles Blancho; Bernard Vanhove","Institut National de la Santé Et de la Recherche Médicale, Unité mixte de Recherche 1064, Nantes, France; Institut National de la Santé Et de la Recherche Médicale, Unité mixte de Recherche 892, Nantes, France; Cellular and Tissular Imaging Core Facility (MicroPICell), Nantes, France; Effimune S.A.S, Nantes, France; Centre Hospitalier Universitaire de Nantes, Institut de Transplantation Urologie Néphrologie, Nantes, France; Université de Nantes, Faculté de Médecine, Nantes, France","Conceived and designed the experiments: ND NP BV. Performed the experiments: ND NP PH FC CM SV. Analyzed the data: ND NP GB BV. Contributed reagents/materials/analysis tools: PH HV BC. Wrote the paper: ND BV. Assisted in the use of the time-lapse microscope: PH.","This study was partly supported by Effimune through a joint grant with the French ANRS, in the framework of a CIFRE convention. The authors have the following interests. Caroline Mary and Nicolas Poirier are employed by Effimune S.A.S. and Bernard Vanhove is a consultant. Effimune is a biotech company developing CD28 antagonists such as those used in this manuscript. There are no patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2013","12","Nahzli Dilek","ND",10,TRUE,3,6,4,2,TRUE,TRUE,FALSE,0,NA,FALSE
